June, 2019 | sermonix pharmaceutical

Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Treating ER+ Metastatic Breast Cancer Patients With ESR1 Mutations

by Sermonix Pharmaceuticals | Jun 3, 2019 | News

Sermonix-sponsored University of Chicago preclinical investigation demonstrated: Lasofoxifene alone was significantly more effective than fulvestrant at inhibiting metastasis of both MCF7-Y537S and D538G tumors to the lungs and liver.Lasofoxifene, in combination with...

Lasofoxifene Shows Promise as Treatment for ER-Positive Metastatic Breast Cancer

by Sermonix Pharmaceuticals | Jun 2, 2019 | News

CHICAGO—Findings suggest that lasofoxifene, in combination with CDK4/6 inhibitors like palbociclib, is a promising approach for the treatment of endocrine therapy resistant ER+ metastatic breast cancer patients (Abstract 1056). “Lasofoxifene is a legacy molecule...

Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Treating ER+ Metastatic Breast Cancer Patients With ESR1 Mutations

Lasofoxifene Shows Promise as Treatment for ER-Positive Metastatic Breast Cancer

Recent Posts

Recent Comments

Archives

Categories

Meta